Akums reports Q4 FY25 with 12.4% revenue growth
Akums invested Rs. 272 crore in capital expenditure during FY25
Akums invested Rs. 272 crore in capital expenditure during FY25
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
EBITDA before special items decreases to €4.08 billion (7.4%)
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
Subscribe To Our Newsletter & Stay Updated